➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Moodys
Johnson and Johnson
Harvard Business School
McKesson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TALZENNA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Talzenna

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03875313 Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Recruiting Calithera Biosciences, Inc Phase 1/Phase 2 2019-03-01 This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the PARP inhibitor talazoparib in participants with advanced/metastatic solid tumors.
NCT03964532 TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Recruiting Pfizer Phase 1/Phase 2 2019-04-17 This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.
NCT03964532 TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Recruiting Georgetown University Phase 1/Phase 2 2019-04-17 This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.
NCT03974217 Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Not yet recruiting Pfizer Phase 1 2019-06-01 This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.
NCT03974217 Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Not yet recruiting Dana-Farber Cancer Institute Phase 1 2019-06-01 This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.
NCT03990896 Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Not yet recruiting Pfizer Phase 2 2019-07-31 This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
NCT03990896 Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Not yet recruiting Massachusetts General Hospital Phase 2 2019-07-31 This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Talzenna

Condition Name

Condition Name for Talzenna
Intervention Trials
Breast Cancer 2
Solid Tumor 2
Fallopian Tube Cancer 1
Stage IVB Lung Cancer AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Talzenna
Intervention Trials
Breast Neoplasms 3
Lung Neoplasms 2
Triple Negative Breast Neoplasms 2
Melanoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Talzenna

Trials by Country

Trials by Country for Talzenna
Location Trials
United States 9
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Talzenna
Location Trials
Massachusetts 2
Texas 2
New York 1
Ohio 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Talzenna

Clinical Trial Phase

Clinical Trial Phase for Talzenna
Clinical Trial Phase Trials
Phase 2 5
Phase 1/Phase 2 5
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Talzenna
Clinical Trial Phase Trials
Not yet recruiting 9
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Talzenna

Sponsor Name

Sponsor Name for Talzenna
Sponsor Trials
Pfizer 5
National Cancer Institute (NCI) 2
Ulrik Lassen 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Talzenna
Sponsor Trials
Industry 15
Other 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
Express Scripts
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.